Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...
Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...
Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...
In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...
Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...
As biopharma and healthcare companies face a rapidly shifting regulatory environment, marketing and advisory firm Avalere ...
With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...
In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Andrew Willett discussed the path that led him to Lundbeck and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback